BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sinden NJ, Stockley RA. Proteinase 3 activity in sputum from subjects with alpha-1-antitrypsin deficiency and COPD. Eur Respir J. 2013;41:1042-1050. [PMID: 22936713 DOI: 10.1183/09031936.00089712] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Stone H, Pye A, Stockley RA. Disease associations in alpha-1-antitrypsin deficiency. Respir Med. 2014;108:338-343. [PMID: 24176989 DOI: 10.1016/j.rmed.2013.10.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
2 Stockley RA. Alpha-1 Antitrypsin Deficiency: Have We Got the Right Proteinase? Chronic Obstr Pulm Dis 2020;7:163-71. [PMID: 32396717 DOI: 10.15326/jcopdf.7.3.2019.0151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Nurwidya F, Damayanti T, Yunus F. The Role of Innate and Adaptive Immune Cells in the Immunopathogenesis of Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis (Seoul) 2016;79:5-13. [PMID: 26770229 DOI: 10.4046/trd.2016.79.1.5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
4 Sinden NJ, Baker MJ, Smith DJ, Kreft JU, Dafforn TR, Stockley RA. α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2015;308:L179-90. [PMID: 25416382 DOI: 10.1152/ajplung.00179.2014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
5 N'Guessan K, Grzywa R, Seren S, Gabant G, Juliano MA, Moniatte M, van Dorsselaer A, Bieth JG, Kellenberger C, Gauthier F, Wysocka M, Lesner A, Sienczyk M, Cadene M, Korkmaz B. Human proteinase 3 resistance to inhibition extends to alpha-2 macroglobulin. FEBS J 2020;287:4068-81. [PMID: 31995266 DOI: 10.1111/febs.15229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Schouten IGM, Mumford RA, Moes DJAR, Hiemstra PS, Stolk J. The Course of AαVal541 as a Proteinase 3 Specific Neo-Epitope after Alpha-1-Antitrypsin Augmentation in Severe Deficient Patients. Int J Mol Sci 2021;22:8031. [PMID: 34360796 DOI: 10.3390/ijms22158031] [Reference Citation Analysis]
7 Mårdh CK, Root J, Uddin M, Stenvall K, Malmgren A, Karabelas K, Thomas M. Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease. J Immunol Res 2017;2017:5273201. [PMID: 28596972 DOI: 10.1155/2017/5273201] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
8 Chen Y, Liu Z, Pan T, Chen E, Mao E, Chen Y, Tan R, Wang X, Tian R, Liu J, Qu H. JMJD3 is involved in neutrophil membrane proteinase 3 overexpression during the hyperinflammatory response in early sepsis. Int Immunopharmacol 2018;59:40-6. [PMID: 29621735 DOI: 10.1016/j.intimp.2018.03.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
9 Crisford H, Sapey E, Stockley RA. Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases. Respir Res 2018;19:180. [PMID: 30236095 DOI: 10.1186/s12931-018-0883-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
10 Stockley RA. Biomarkers in chronic obstructive pulmonary disease: confusing or useful? Int J Chron Obstruct Pulmon Dis 2014;9:163-77. [PMID: 24532968 DOI: 10.2147/COPD.S42362] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
11 Jasper AE, McIver WJ, Sapey E, Walton GM. Understanding the role of neutrophils in chronic inflammatory airway disease. F1000Res 2019;8:F1000 Faculty Rev-557. [PMID: 31069060 DOI: 10.12688/f1000research.18411.1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 21.5] [Reference Citation Analysis]
12 Budnjo A, Narawane S, Grauffel C, Schillinger AS, Fossen T, Reuter N, Haug BE. Reversible ketomethylene-based inhibitors of human neutrophil proteinase 3. J Med Chem 2014;57:9396-408. [PMID: 25365140 DOI: 10.1021/jm500782s] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
13 Korkmaz B, Lesner A, Guarino C, Wysocka M, Kellenberger C, Watier H, Specks U, Gauthier F, Jenne DE. Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease. Pharmacol Rev 2016;68:603-30. [PMID: 27329045 DOI: 10.1124/pr.115.012104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
14 Weiss SAI, Rehm SRT, Perera NC, Biniossek ML, Schilling O, Jenne DE. Origin and Expansion of the Serine Protease Repertoire in the Myelomonocyte Lineage. Int J Mol Sci 2021;22:1658. [PMID: 33562184 DOI: 10.3390/ijms22041658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Hughes MJ, Sapey E, Stockley R. Neutrophil phenotypes in chronic lung disease. Expert Rev Respir Med 2019;13:951-67. [PMID: 31394045 DOI: 10.1080/17476348.2019.1654377] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
16 Sinden NJ, Koura F, Stockley RA. The significance of the F variant of alpha-1-antitrypsin and unique case report of a PiFF homozygote. BMC Pulm Med 2014;14:132. [PMID: 25098359 DOI: 10.1186/1471-2466-14-132] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
17 Newby PR, Crossley D, Crisford H, Stockley JA, Mumford RA, Carter RI, Bolton CE, Hopkinson NS, Mahadeva R, Steiner MC, Wilkinson TMA, Sapey E, Stockley RA. A specific proteinase 3 activity footprint in α1-antitrypsin deficiency. ERJ Open Res 2019;5:00095-2019. [PMID: 31403052 DOI: 10.1183/23120541.00095-2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Brebner JA, Stockley RA. Recent advances in α-1-antitrypsin deficiency-related lung disease. Expert Review of Respiratory Medicine 2014;7:213-30. [DOI: 10.1586/ers.13.20] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
19 Ungurs MJ, Sinden NJ, Stockley RA. Progranulin is a substrate for neutrophil-elastase and proteinase-3 in the airway and its concentration correlates with mediators of airway inflammation in COPD. American Journal of Physiology-Lung Cellular and Molecular Physiology 2014;306:L80-7. [DOI: 10.1152/ajplung.00221.2013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
20 Carter RI, Ungurs MJ, Pillai A, Mumford RA, Stockley RA. The Relationship of the Fibrinogen Cleavage Biomarker Aα-Val360 With Disease Severity and Activity in α1-Antitrypsin Deficiency. Chest 2015;148:382-8. [PMID: 25569856 DOI: 10.1378/chest.14-0520] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
21 Rønnow SR, Langholm LL, Sand JMB, Thorlacius-Ussing J, Leeming DJ, Manon-Jensen T, Tal-Singer R, Miller BE, Karsdal MA, Vestbo J. Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort. Sci Rep 2019;9:4064. [PMID: 30858579 DOI: 10.1038/s41598-019-40785-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
22 Crapo J, Gupta A, Lynch DA, Vogel-Claussen J, Watz H, Turner AM, Mroz RM, Janssens W, Ludwig-Sengpiel A, Beck M, Langellier B, Ittrich C, Risse F, Diefenbach C. FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD. BMJ Open 2021;11:e042526. [PMID: 33753437 DOI: 10.1136/bmjopen-2020-042526] [Reference Citation Analysis]
23 Tsantikos E, Lau M, Castelino CM, Maxwell MJ, Passey SL, Hansen MJ, McGregor NE, Sims NA, Steinfort DP, Irving LB, Anderson GP, Hibbs ML. Granulocyte-CSF links destructive inflammation and comorbidities in obstructive lung disease. J Clin Invest 2018;128:2406-18. [PMID: 29708507 DOI: 10.1172/JCI98224] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
24 Stockley RA. Alpha1-antitrypsin Review. Clinics in Chest Medicine 2014;35:39-50. [DOI: 10.1016/j.ccm.2013.10.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
25 Dey T, Kalita J, Weldon S, Taggart CC. Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease. J Clin Med 2018;7:E244. [PMID: 30154365 DOI: 10.3390/jcm7090244] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
26 Chen KJ, Chen YL, Ueng SH, Hwang TL, Kuo LM, Hsieh PW. Neutrophil elastase inhibitor (MPH-966) improves intestinal mucosal damage and gut microbiota in a mouse model of 5-fluorouracil-induced intestinal mucositis. Biomed Pharmacother 2021;134:111152. [PMID: 33373916 DOI: 10.1016/j.biopha.2020.111152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Stockley RA, Turner AM. α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends in Molecular Medicine 2014;20:105-15. [DOI: 10.1016/j.molmed.2013.11.006] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
28 Sabbagh DK, Barmayehvar B, Nguyen T, Edgar RG, Turner AM. Managing panniculitis in alpha-1 antitrypsin deficiency: Systematic review of evidence behind treatment. WJD 2018;7:1-8. [DOI: 10.5314/wjd.v7.i1.1] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]